- Home
- KZIA vs AYTU Comparison
KZIA vs AYTU Comparison
Compare KZIA & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- AYTU
- Stock Information
- Founded
- KZIA 1994
- AYTU N/A
- Country
- KZIA Australia
- AYTU United States
- Employees
- KZIA N/A
- AYTU N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- AYTU Health Care
- Exchange
- KZIA Nasdaq
- AYTU Nasdaq
- Market Cap
- KZIA 11.7M
- AYTU 9.6M
- IPO Year
- KZIA 1999
- AYTU N/A
- Fundamental
- Price
- KZIA $8.68
- AYTU $2.48
- Analyst Decision
- KZIA Strong Buy
- AYTU Strong Buy
- Analyst Count
- KZIA 2
- AYTU 2
- Target Price
- KZIA $14.00
- AYTU $10.00
- AVG Volume (30 Days)
- KZIA 675.5K
- AYTU 156.0K
- Earning Date
- KZIA 08-12-2025
- AYTU 09-25-2025
- Dividend Yield
- KZIA N/A
- AYTU N/A
- EPS Growth
- KZIA N/A
- AYTU N/A
- EPS
- KZIA N/A
- AYTU N/A
- Revenue
- KZIA $1,549,158.00
- AYTU $81,659,000.00
- Revenue This Year
- KZIA N/A
- AYTU N/A
- Revenue Next Year
- KZIA $49.25
- AYTU $1.05
- P/E Ratio
- KZIA N/A
- AYTU N/A
- Revenue Growth
- KZIA 248983.08
- AYTU 0.41
- 52 Week Low
- KZIA $2.86
- AYTU $0.95
- 52 Week High
- KZIA $39.05
- AYTU $2.85
- Technical
- Relative Strength Index (RSI)
- KZIA 50.61
- AYTU 55.21
- Support Level
- KZIA $7.40
- AYTU $2.32
- Resistance Level
- KZIA $10.08
- AYTU $2.82
- Average True Range (ATR)
- KZIA 0.78
- AYTU 0.16
- MACD
- KZIA -0.29
- AYTU -0.02
- Stochastic Oscillator
- KZIA 42.38
- AYTU 34.62
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.